- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.03. | In fiery SOTU, Biden proclaims "We finally beat big pharma" | ||
| 08.03. | NHS App updates 'will tap into smart device data' | ||
| 08.03. | MindMed gets FDA breakthrough tag for LSD in anxiety | ||
| 08.03. | BeiGene breaks new ground for BTK drugs in blood cancers | ||
| 08.03. | Novo Nordisk's oral amycretin tops Wegovy in obesity trial | ||
| 07.03. | UK access disparity resolved as NICE backs RCC therapy | ||
| 07.03. | GSK scores again with Blenrep in multiple myeloma | ||
| 07.03. | Gilead and MSD say weekly oral therapy controls HIV | ||
| 07.03. | Boundless Bio files IPO, and other biotech financings | ||
| 06.03. | UK Chancellor trumpets £650m AstraZeneca investment | ||
| 06.03. | Bayer CEO pulls back from breakup of 'badly broken' group | ||
| 06.03. | Sandoz gets first FDA OK for denosumab biosimilars | ||
| 06.03. | NICE no follows Scottish aye for rare disease drug Xenpozyme | ||
| 06.03. | FDA clears first OTC glucose biosensor, from Dexcom | ||
| 05.03. | Surprise Enhertu rejection follows NICE process change | ||
| 05.03. | Novo Nordisk looks set to add another string to Ozempic bow | ||
| 05.03. | RYSE's $50m digital health fund makes first investment | ||
| 05.03. | Ransom speculation as US reels from health cyberattack | ||
| 05.03. | Pharma's Medicare counteroffers are all in, says HHS | ||
| 05.03. | NICE backs frontline use of Jemperli in endometrial cancer | ||
| 04.03. | Cannabinoids show promise in acute migraine clinical trial | ||
| 04.03. | Bayer pays $310m for Euro rights to ATTR therapy acoramidis | ||
| 04.03. | EMA starts twin reviews of AZ, Daiichi's Dato-DXd | ||
| 04.03. | RNA therapy firm Avidity files $400m placement | ||
| 04.03. | Judge knocks back AstraZeneca's IRA challenge |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
